Moleculin Biotech Inc (MBRX)
4.93
-0.22
(-4.27%)
USD |
NASDAQ |
May 24, 16:00
5.06
+0.13
(+2.64%)
After-Hours: 20:00
Moleculin Biotech Research and Development Expense (Quarterly): 4.252M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 4.252M |
| December 31, 2023 | 6.632M |
| September 30, 2023 | 3.28M |
| June 30, 2023 | 3.888M |
| March 31, 2023 | 5.687M |
| December 31, 2022 | 4.178M |
| September 30, 2022 | 5.965M |
| June 30, 2022 | 4.204M |
| March 31, 2022 | 4.62M |
| December 31, 2021 | 3.179M |
| September 30, 2021 | 4.095M |
| June 30, 2021 | 3.039M |
| March 31, 2021 | 4.105M |
| December 31, 2020 | 1.786M |
| September 30, 2020 | 4.435M |
| June 30, 2020 | 3.329M |
| March 31, 2020 | 3.206M |
| Date | Value |
|---|---|
| December 31, 2019 | 3.197M |
| September 30, 2019 | 2.785M |
| June 30, 2019 | 2.099M |
| March 31, 2019 | 2.932M |
| December 31, 2018 | 2.927M |
| September 30, 2018 | 1.332M |
| June 30, 2018 | 4.231M |
| March 31, 2018 | 1.237M |
| December 31, 2017 | 2.285M |
| September 30, 2017 | 1.061M |
| June 30, 2017 | 0.515M |
| March 31, 2017 | 0.683M |
| December 31, 2016 | 0.88M |
| September 30, 2016 | 0.497M |
| June 30, 2016 | 0.105M |
| March 31, 2016 | 0.015M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.786M
Minimum
Dec 2020
6.632M
Maximum
Dec 2023
3.898M
Average
3.992M
Median
Research and Development Expense (Quarterly) Benchmarks
| Merck & Co Inc | 3.992B |
| Lixte Biotechnology Holdings Inc | 0.1191M |
| Moderna Inc | 1.063B |
| NovaBay Pharmaceuticals Inc | 0.019M |
| Palatin Technologies Inc | 7.160M |